The 9MMMetastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Metastatic Pancreatic Adenocarcinoma, refers to a type of pancreatic cancer that has widen from its original site to other parts of the body system. Pancreatic adenocarcinoma is the most commonly found pancreatic cancer, accounting for nearly 85-90% of cases. When the cancer metastasizes, it means that cancer cells has started invading through the bloodstream or lymphatic system and formed new tumors in distant organs or tissues.
Report has covered granular-level analysis in each mapped market
Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC), Disease Burden Analysis: (Result shown here is reflecting from studies metanalysis, and CSP Analytics Soutions Analysis)
The incidence of metastatic pancreatic ductal adenocarcinoma (mPDAC) is approximately 4.2 per 100 000 globally
Highest incidence reported in Europe, North America, and Australia
It is estimated that in highly developed countries, the 5-year survival rate of patients with PDAC, from the moment of diagnosis, ranges between 8 and 14%
Of all the PDAC cases, nearly up to 20% are hereditary in nature
The number of deaths expected to increase by approximately 40% by time frame of 2040
An annual incidence cases in United States is approximately 58,521
Treatment Landscape:
Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) market is struggling to get an effective treatment
Advancement in biomarkers is essential for developing a targeted therapies
Chemotherapy is currently the mainstay of systemic therapy for patients with metastatic PDAC (mPDAC)
The development of biomarker based treatment expected to change the therapeutic landscape of Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC)
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each therapy type:
Report has examined the how many and what type of cases refer to which type of therapy based on experts opinion analysis.
Report also examined Approaches for Management
First-line of therapy
Second-line of therapy
Third-line of therapy
Drug
Targeted Patient Segment
Chemotherapy
XX
Targeted Therapy
XX
Immunotherapy
XX
Therapies Targeting Tumor Microenvironment and Metabolomics
XX
Targeting Stroma
XX
Upcoming Therapy Assessment (Pipeline Analysis)
Report also provided promising therapy assessment including drugs, existing therapies and upcoming therapy
Novel drug target assessment
Expected launch of key pipeline assets
Promising molecules advantages offer over existing therapy
Therapies Targeting Tumor Microenvironment and Metabolomics
Targeting Stroma
By Line of Therapy:
First-line of therapy
Second-line of therapy
Third-line of therapy
By Gender:
Male
Female
Market Dynamics: Explored in the report
Untreated Prevalent Pool of Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC)
Significant development in biomarkers
Conducive reimbursement, pricing strategies, and market access ecosystems
Huge medical unmet need
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Lack of timely diagnosis
Research gap
Cost of therapy
Treatment compliance and adherence
Recent Developments:
Feb., 2024: FDA approved supplemental new drug application for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX)as a first-line of therapy in adults living with metastatic pancreatic adenocarcinoma (mPDAC).
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
5-Europe Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
Ipsen Pharma
AstraZeneca
Bristol Myers Squibb (BMS)
Merck & Co. (MSD outside the United States and Canada)
Roche/Genentech
Eli Lilly and Company
Celgene
BioNTech
Halozyme Therapeutics
Novartis
Others
Reason to buy this report:
Fostering Understanding on Metastatic Pancreatic ductal Adenocarcinoma/Cancer (mPDAC) Drug Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
